|
Xarelto Wins Indications for Blood Clot Treatment, Recurrent Risk Reduction
The FDA has approved new indications for Janssen Pharmaceuticals’ Xarelto to treat deep vein thrombosis (DVT) or pulmonary embolism (PE) and to reduce the risk of recurrent DVT and PE following initial treatment.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives